Lupin bags USFDA okay for seizure treatment drug Rufinamide

Rufinamide Tablets will be manufactured at Lupin’s facility in Goa, India.

Published On 2022-08-18 09:53 GMT   |   Update On 2022-08-18 09:53 GMT
Advertisement

Mumbai: Global pharma major, Lupin Limited, today announced that the company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Rufinamide Tablets USP, 100 mg, 200 mg, and 400 mg.

The product is a generic equivalent of Banzel Tablets, 100 mg, 200 mg, and 400 mg, of Eisai Inc. 

Rufinamide is used with other medications to control seizures in patients who have Lennox-Gastaut syndrome. Rufinamide belongs to a class of drugs known as Anticonvulsants.

Advertisement

Rufinamide Tablets will be manufactured at Lupin's facility in Goa, India. 

Read also: Lupin gets USFDA nod for partial-onset seizures drug Brivaracetam

Rufinamide Tablets (RLD Banzel) had estimated annual sales of USD 164 million in the U.S. (IQVIA MAT June 2022).

Medical Dialogues Team had earlier announced that the company had received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

Read also: Lupin gets USFDA nod for partial-onset seizures drug Brivaracetam

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.

Read also: Lupin secures USFDA nod for Azilsartan Medoxomil Tablets

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News